Media OutReach
Uni-Bio Science Group Limited Announces 2024 Annual Results
Record-Breaking Revenue of HK$553.0M and Net Profit of HK$82.8M First-ever Dividend was HK$0.277 Cents Per Share Strengthening Presence in Osteoporosis, Ophthalmology, and Aesthetic Medical Markets
HONG KONG SAR – EQS Newswire – 27 March 2025 – A fully integrated biopharmaceutical company – Uni-Bio Science Group Limited (“Uni-Bio Science”, together with its subsidiaries referred to as the “Group”, stock code: 0690.HK), is pleased to announce its annual results for the year ended 31 December 2024 (the “Period”).
Key Accomplishments in 2024
During the Year, the Group achieved a spectrum of accomplishments, for both of its marketed products and innovative biologics. The key highlights include:
1. The Group recorded a 14.1% year-on-year (“YoY”) increase in revenue, reaching approximately HK$553.0 million. With its approval in January 2024 and subsequent launch in March 2024, Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations.
2. Profit for the Year soared by16.8% YoY to approximately HK$82.8 million, marking a historic high. These results reaffirm the Group’s solid market position and its ability to deliver sustainable, high-quality growth as a leading biopharmaceutical company.
3. The board of directors (“Board”) has declared a dividend payment for 2024 of HK$0.277 cents per share, marking the historic first for the Company. This is particularly encouraging, as it represents an important milestone for a research-oriented biopharmaceutical company. The Board is also pleased to announce the approval and adoption of a dividend payout policy of no less than 20% of its net profit for the current year.
4. In January 2024, the China National Medical Products Administration (“NMPA”) officially approved the launch of Bogutai®, marking a major breakthrough for the Group in osteoporosis and orthopedic disease management. Since its market debut in early 2024, Bogutai® has gained remarkable traction, achieving a patient retention rate exceeding 70%.
5. In December 2024, the Group successful launch its self-developed medical aesthetics product, 肌顏態®. The recombinant collagen dressing, developed in collaboration with Chongqing Minji Medical Device Co., Ltd., received Class II medical device approval, reinforcing the Group’s commitment to innovative skin repair solutions.
6. In January 2024, the NMPA officially accepted the marketing application for Diquafosol Sodium eye drops, marking a key milestone in the Group’s ophthalmology drug pipeline. During the Year, the Group has already submitted additional data to the Center for Drug Evaluation (CDE). Diquafosol Sodium is expected to receive the marketing approval in the first half of 2025.
7. During the Year, the Group completed the pharmaceutical research and pre-Bioequivalence studies of Esaconazole sulfoate capsules. The formal Bioequivalence trials has been initiated in 2025 to accelerate the launch process.
8. In May 2024, the Group cooperated with Great Bay Bio (GBB) and Pebble Accelerator, a subsidiary of Tigermed to joint development of innovative weight reduction drugs, aiming to revolutionize the treatment of obesity. Through this collaboration, we seek to establish a comprehensive ecological industry chain, spanning from target discovery to antibody generation, druggability verification, process development, clinical pipeline, and ultimately, commercialization.
Annual Results
In 2024, the Group recorded a revenue of approximately HK$553.0 million, representing an increase of 14.1% YoY. The increase in revenue was mainly attributable to the favorable sales performance of the Group’s newly launched product Bogutai®. The Group’s newly launched product Bogutai® achieved sales of HK$62.9 million, exceeding initial expectations. Pinup® recorded a decrease of 2.9% in revenue from approximately HK$247.4 million to approximately HK$240.3 million for the Year. During the Year, the Group was re-selected for the centralized procurement, with a validity period of two years. However, the Group adopted a more selective approach to supplying hospitals in response to certain local policy adjustments. During the Year, revenue generated from GeneTime® was approximately HK$197.9 million, representing an increase of 6.7% YoY. The increase was attributed to the expansion of the Group’s hospital network and additional sales channels beyond hospitals, such as pharmacies and e-commerce platforms. GeneSoft® recorded an increase in revenue from approximately HK$41.3 million to approximately HK$42.5 million, representing an increase of 2.9% YoY. Revenue from Boshutai® declined from approximately HK$10.4 million to approximately HK$9.4 million, representing a decrease of 10.2%. During the Year, Boshutai® was successfully included in the centralized procurement by the Henan Seventeen Provinces Alliance and the procurement validity period is set for two years, which secured the Group with new in-hospital orders.
Prospects
Recent advancements in biotechnology, coupled with strong government support, position China’s pharmaceutical landscape for substantial growth, with a projected compound annual growth rate (CAGR) of 7.5% from 2024 to 2032, according to the IMARC Group. This expansion is driven by technological innovations and a growing elderly population increasingly susceptible to chronic conditions such as diabetes, which boosts pharmaceutical demand. Concurrently, the aesthetic medical sector is emerging as a significant market force, with forecasts indicating a CAGR of 10% to 15% from 2024 to 2027, primarily fueled by rising beauty standards and increased spending among individuals with moderate to high incomes. With the two industries being the Group’s core R&D focuses going forward, it showcases a great potential for the Group to rapidly grow and capture the market shares.
Mr. Kingsley Leung, Chairman of Uni-Bio Science commented, “I am proud to announce that we have reached significant milestones this year, both financially and operationally. As our efforts begin to bear fruit, I am deeply grateful for the unwavering, long-term support of our shareholders. In recognition of this, I am delighted to share two landmark decisions: the declaration of our inaugural dividend and the establishment of a forward-looking dividend payout policy of no less than 20% of its net profit for the current year. These actions reaffirm our steadfast commitment to delivering on our objectives while creating and sustaining value for our shareholders.
Looking forward, we remain steadfast in our commitment to innovation and seizing opportunities within both the pharmaceutical and aesthetic medical sectors. Our vision has consistently focused on diversifying our product offerings while leveraging our strengths in endocrinology, ophthalmology, and dermatology. We are delighted to announce the successful launch of Bogutai® Following this milestone, we will continue to develop best-in-class products, including a PTH microneedle formulation that is less invasive and offers higher bioavailability, as well as a novel antibody drug for weight loss. Significant advancements have also been made in our series of EGF products. Preparations for pilot plant testing of the EGF hydrogel are underway, and Diquafosol Sodium Eye Drop slated for launch in the second quarter of 2025. Additionally, The formal Bioequivalence trials for Esaconazole sulfoate capsules has been initiated in 2025 to accelerate the launch process.
In the aesthetic medical segment, we are excited about the launch of肌顏態® in late December 2024. Building on this momentum, we will accelerate the introduction of other new product lines in 2025 based on Skbrella™ FN. Additionally, we plan to introduce collagen and beauty peptides as advanced skincare raw materials this year. By leveraging our expertise in GeneTime® and 肌顏態®, we aim to create a comprehensive skincare solution for emergency skin repair and stabilization. To foster our product innovation, we are utilizing two new key technology platforms: advanced synthetic biology platform and hydrogel technology. These platforms are expected to drive our product expansion.
To enhance our reach and support product launches, we are expanding our sales channels beyond traditional public and private hospital networks to include pharmacies, online platforms, and aesthetic medical institutions. We are also exploring international markets to bolster our global presence. By adopting a diversified distribution strategy, the Group aims to secure future sales growth while reducing its dependence on regional markets and traditional channels. In support of our company’s growth, the infrastructure for our new factory in Dongguan was fully completed in 2024, marking a significant milestone in our expansion plans. A state-of-the-art BFS packaging line has also been featured, which we believe will enable the Group to command a premium in the market. With these strategic focuses and our commitment to rapid advancement, the Group is well-positioned to solidify its leadership in these dynamic industries and achieve lasting success in the years ahead.”
Hashtag: #Uni-BioScience
The issuer is solely responsible for the content of this announcement.
About Uni-Bio Science Group Limited
Uni-Bio Science Group Limited is principally engaged in the research and development, manufacture and sales of pharmaceutical products. The research and development center is fully equipped with a complete system for the development of genetically-engineered products with a pilot plant test base which is in line with NMPA requirements. The Group also has three GMP manufacturing bases in Beijing, Dongguan and Shenzhen. The Group also has a highly efficient commercialization platform and marketing network. The Group focuses on the development of novel treatments and innovative drugs addressing the therapeutic areas of endocrine such as diabetes and osteoporosis, ophthalmology and dermatology.
Uni-Bio Science Group Limited was listed on the Main Board of the Hong Kong Stock Exchange on November 12, 2001. Stock code: 0690.
For further information, please contact: [email protected]
Media OutReach
No Judgement, No Awkwardness: More Hongkongers Are Opening Up to AI for Mental Health Support
A newly completed Hong Kong study suggests there may finally be a way to bridge that gap. The AIM Greater China Psychology Research Group has completed a Hong Kong-based study conducted in the 2025–2026 academic year, comparing the effectiveness of human hypnotherapists against AI in delivering hypnotic experience-based stress relief experiences. The findings were striking: a significant proportion of participants felt that both approaches yielded virtually equivalent levels of relaxation — and more than 60% reported preferring their AI session after the fact.
Over 400 Applicants: A Reflection of a Generation in Need of Being Heard
The research team recruited participants experiencing family-related stress via Facebook. Within a short period of the post going live, over 400 individuals voluntarily applied — a figure that speaks not only to the pervasiveness of stress in modern life, but also to a growing willingness among the public to prioritise their own emotional wellbeing and actively seek self-care solutions.
From the applicant pool, 48 participants were randomly selected to take part. Each participant underwent two separate hypnotic experience stress relief audio sessions, each lasting approximately one hour — one recorded by a human hypnotherapist, and one fully generated by AI, including both the script and voice. Participants then compared their personal experiences of both sessions.
What Humans Can Do, AI Can Do Too
In the most critical area of comparison — stress relief effectiveness — the largest single group of participants (41.7%) rated the AI and human sessions as equally effective. On a scoring basis, the AI hypnotic experience averaged approximately 2.92 points, compared to 2.58 points for the human session — with AI coming out marginally ahead.
The study further found that nearly 90% of participants indicated they would enjoy a session if it genuinely helped them feel relaxed. In other words, what people truly care about is whether it works — not whether the voice behind it belongs to a human or a machine. On this front, AI has passed the test.
Over 60% More Willing to Share Their Feelings with AI
The results around personal preference were perhaps the most eye-opening. When asked which session they enjoyed more, 62.5% of participants chose the AI experience — and among women, that number climbed even higher, to 68.4%.
So what made AI the preferred choice? Researchers believe it comes down to one simple thing: feeling safe. With AI, there is no worry about being judged. No fear of saying the wrong thing. No awkwardness. About 1 in 4 participants said they actually found it easier to talk openly with AI — because it communicates in a way that feels clear, calm, and natural, much like everyday conversation.
The truth is, some things are just easier to say when no one is watching. That is not a flaw in human nature — it is simply how many of us work.
When it came to privacy, the findings were equally reassuring. More than half of all participants said they had no concerns about AI handling their personal information. Only a very small number — just 2.08% — said they felt uncomfortable. This points to a growing sense of trust in AI tools among the general public.
AI Reads the Data; Therapists Read the Person
Beyond the hypnotic experience itself, the local research team also evaluated AI’s capability as an analytical tool — with equally impressive results.
AI was able to rapidly process large volumes of participant responses, objectively assess individual stress levels, and identify underlying patterns. For instance, AI identified that 35% of participants independently expressed a desire for “personal space” or “better soundproofing” in their homes. On the surface, these may seem like trivial lifestyle concerns — yet AI connected this pattern to the reality of Hong Kong residents living in constrained spaces, highlighting a deeper psychological sense of having “nowhere to breathe”. This level of insight would be difficult to uncover through manual review of dozens of questionnaires alone.
AI also observed that many participants habitually occupied the role of “problem-solver” or “mediator” within their households, suppressing their own emotional needs in the process. Researchers noted that this reflects a widely recognised social phenomenon — the pressures faced by eldest daughters and the so-called “sandwich generation,” caught between the responsibilities of caring for ageing parents and raising children. AI’s ability to rapidly identify these hidden emotional burdens allows therapists to bypass lengthy preliminary assessments and focus more swiftly on the core issues that require their attention.
AI Is Here to Help, Not to Take Over
The local research team emphasises that the study was never intended to position AI as a replacement for human therapists. Rather, the aim is to explore how the two can work in tandem. Much like how blood test reports assist physicians in diagnosis, AI can play an analogous supporting role in the mental health field — organising data, identifying patterns, and lowering barriers to seeking help, so that mental health professionals can direct their energy towards the moments that truly require a human touch.
Those who proactively seek psychological support remain a minority, often deterred by the fear of inconvenience, social stigma, or the awkwardness of speaking up. If AI can serve as the bridge that encourages more people to take that first step, that alone may be its most meaningful contribution to society.
Hashtag: #HypnosisInstitute
The issuer is solely responsible for the content of this announcement.
About Hypnosis Institute
Hypnosis Institute is dedicated to helping people in Hong Kong lead healthier and more fulfilling lives through hypnotic experience. We offer accessible and practical hypnotic experience training programmes designed to integrate hypnotic techniques into everyday life, with a focus on stress management, emotional wellbeing, and personal growth.
Hypnosis Institute is Hong Kong’s only hypnotic experience professional development platform that simultaneously operates a research group, social innovation group, practical training group, crisis psychological support group, charitable initiatives, networking events, therapeutic services, and a comprehensive training pathway.
As the sole Hong Kong chapter of the Association for Integrative Medicine (AIM) in the United States, the sole overseas Hong Kong academy of UK educational institution Study House (Quality Licence Scheme), and the sole specialist hypnotic experience training school in Hong Kong under Cambridge International College in the United Kingdom, Hypnosis Institute provides internationally recognised qualifications that contribute to the advancement of the industry.
Founder Charles Leung is a trainer of trainers in the field of hypnotic experience, and has been specially appointed by the Association for Integrative Medicine as the Chief Instructor for Specialist hypnotic experience in Greater China. He has trained over 1,000 hypnotherapists and instructors, upholding the highest standards of professional development in the mental health field.
The Institute’s programmes integrate a comprehensive range of methodologies, including hypnotic experience combined with MBTI personality profiling, DISC behavioural analysis, mental health coaching, emotional education, and the HiddenMe Cards inner child tool — providing a holistic and personalised approach to hypnotic experience practice. Instructors specialise in paediatric hypnotic experience, Internal Family Systems (including inner child) hypnotic experience, stress and insomnia relief hypnotic experience, interpersonal relationship hypnotic experience, as well as hypnotic experience in reminiscence and palliative care.
Driven by the belief that everyone can harness the power of hypnotic experience to enhance their mental wellbeing, Hypnosis Institute is committed to sharing psychological knowledge and providing professional support in the areas of emotional management, life challenges, and the professional development of the hypnotic experience industry.
Follow us at hypnosisinstitute.com.hk, 
Facebook, 
Instagram and 
YouTube for the latest updates.
Held at deMori @ FCC Signature, the event featured a live platform demonstration, partner showcase, and networking sessions aimed at facilitating engagement between founders, advisors, and investors.
Introducing CapitalOS
CapitalOS, BizPal’s corporate finance platform, was presented through a live demonstration during the event. The system integrates operational, brand, and financial data into a structured framework designed to support investor readiness and due diligence.
According to BizPal, the platform is intended to help SMEs organise their business information into formats aligned with investor expectations, enabling clearer communication during fundraising discussions.
“SMEs should never walk into a funding conversation unsure of their numbers,” said Ms. Anya Tan, CEO of BizPal Malaysia.
MOUs Expand Distribution Network
The event also included the signing of Memoranda of Understanding between BizPal and two Malaysian partners, My Education Platform and VA Partners. Both organisations will serve as authorised distributors of BizPal’s education and advisory programmes across Malaysia.
The partnerships expand BizPal’s reach within the SME ecosystem by working with local organisations that support business development and capability building.
“Partnering with BizPal allows us to introduce structured, investor-ready methodologies to the SME community we serve,” said Mr. Jeff Lee, Director, My Education Platform.
A representative from VA Partners is expected to provide a statement following final endorsement.
Global Mentorship Exchange (GMX)
During the event, BizPal also presented the Global Mentorship Exchange (GMX), an ecosystem initiative designed to connect experienced business leaders with high-potential entrepreneurs.
The initiative provides a structured environment for mentorship supported by data-based evaluation and standardised assessment criteria aligned with investor expectations. GMX was first introduced during BizPal’s Data Fundraising Masterclass in December 2025 and was presented to a broader network of partners and investors at BizPal Day.
Next Steps
Following the event, BizPal plans to expand the adoption of CapitalOS and continue developing its partner network across Malaysia and the ASEAN region.
Hashtag: #NoDataNoTalk #DataFundraising #InvestorReady #CapitalReadiness #FinTech #BusinessValuation #ASEANSMEs #BizPalDay
https://www.bizpal.tech/
https://www.facebook.com/simplyfi.sg
The issuer is solely responsible for the content of this announcement.
About BizPal
BizPal provides data-driven corporate finance solutions designed to help ASEAN SMEs become investor-ready. Its platform, CapitalOS, integrates operational, strategic, and financial data into a unified system that supports business evaluation and investor engagement.
Media OutReach
Vinhomes Green Paradise Can Gio And IHG Hotels & Resorts Partner To Bring Four International Hotel Brands To The Coastal Mega Urban Development
Under the agreement, IHG will develop four hotels with a total of more than 1,000 rooms at Vinhomes Green Paradise Can Gio, including InterContinental Saigon Can Gio with 400 rooms, Crowne Plaza Saigon Can Gio with 400 rooms, Holiday Inn Express Saigon Can Gio with 130 rooms, and Garner Saigon Can Gio with 130 rooms.
InterContinental Saigon Can Gio, a world-renowned luxury brand, will deliver premium hospitality experiences tailored to international travelers and domestic guests seeking high-end accommodation. Crowne Plaza Saigon Can Gio, one of the largest upscale hotel brands globally, will cater to frequent travelers with modern, flexible spaces designed to optimize productivity and foster connections.
Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio will expand the destination’s accommodation offering with efficient, high-quality stays focused on value, making the development more accessible to a broader range of guests. This also marks the official debut of both brands in the Vietnamese market.
According to the development timeline, Holiday Inn Express Saigon Can Gio and Garner Saigon Can Gio are expected to open in 2028, followed by InterContinental Saigon Can Gio and Crowne Plaza Saigon Can Gio in 2030.
In this partnership, Vinpearl, a member of Vingroup, will act as the project operator and lead the collaboration with IHG Hotels & Resorts, while coordinating with all stakeholders throughout the development and operational phases.
Together with Vinpearl’s world-class hospitality brand, the addition of four premium IHG hotels will help realize a 7,000-room accommodation ecosystem at Vinhomes Green Paradise Can Gio, meeting the growing demand for extended stays and diverse experiences year-round in Can Gio and Ho Chi Minh City.
Complementing the hospitality offering, a series of large-scale entertainment and resort facilities unique to Vinhomes Green Paradise Can Gio will further elevate the destination. These include the 122-hectare VinWonders theme park featuring the world’s tallest artificial snow mountain and nearly 200 attractions, the 5,000-seat Blue Waves Theater, the 800-hectare Paradise Lagoon, the five-star international cruise port Landmark Harbour, and two 18-hole international-standard golf courses. Together, these developments aim to position Can Gio as a globally-recognized tourism and resort hub, targeting 40 million visitors annually and standing alongside leading destinations in Vietnam and worldwide.
Mr. Rajit Sukumaran, Senior Vice President and Managing Director, East Asia & Pacific, IHG Hotels & Resorts, said: “This agreement marks the beginning of a strategic partnership between IHG and Vingroup. Bringing four of our standout brands to Vinhomes Green Paradise Can Gio reflects the diversity of our portfolio, as well as our strong commitment to supporting Vietnam’s goal of becoming a leading global tourism destination. With brands spanning multiple segments, we believe this collaboration will help create an integrated hospitality ecosystem that meets the diverse needs of travelers at one of Vietnam’s most significant developments.”
Ms. Ngo Thi Huong, Chief Executive Officer of Vinpearl Joint Stock Company, said: “We selected IHG not only for its global brand portfolio but also for its proven operational expertise across international markets. Introducing InterContinental, Crowne Plaza, Holiday Inn Express, and Garner to Vinhomes Green Paradise Can Gio is a key step in completing our service structure and establishing international operating standards for the mega project’s hotel system. With this partnership as a foundation, we believe Vinhomes Green Paradise will progressively emerge as a world-class destination, where a fully integrated ecosystem continues to enhance its appeal to residents and both domestic and international visitors.”
Vinhomes Green Paradise is located in the southeastern part of Ho Chi Minh City. Construction began on April 19, 2025, with a total area of 2,870 hectares. The development features three sides facing the sea and is adjacent to the Can Gio Mangrove Biosphere Reserve, a UNESCO-recognized site. The project is being developed to leading ESG++ standards, integrating green, smart, ecological, and regenerative principles.
The development benefits from a well-connected transport infrastructure network, including the Ben Thanh – Can Gio high-speed railway, which will reduce travel time from central Ho Chi Minh City to just 13 minutes, the Can Gio Bridge, the interchange connecting Rung Sac Road with the Ben Luc – Long Thanh Expressway, and the Can Gio – Vung Tau sea-crossing route, enabling travel between two major tourism hubs in just 10 minutes.
With a diverse range of accommodation options, internationally-standardized hotel systems, and a wide array of cultural, artistic, sports, and entertainment facilities aligned with green, smart, and community-friendly principles, Vinhomes Green Paradise Can Gio stands out as a rare mega urban development that both sets new benchmarks for ESG living and delivers a world-class tourism and resort experience.
Hashtag: #Vinhomes
The issuer is solely responsible for the content of this announcement.
About IHG Hotels & Resorts:
IHG Hotels & Resorts is a global hospitality company with a portfolio of 21 brands and IHG One Rewards, one of the world’s largest hotel loyalty programs with over 160 million members. IHG currently franchises, leases, manages, or owns more than 6,900 hotels across over 100 countries, with more than 2,300 hotels in its development pipeline.
IHG’s brand portfolio spans Luxury & Lifestyle, Premium, Essentials, and Suites segments, including well-known brands such as Six Senses, Regent, InterContinental, Crowne Plaza, Holiday Inn Express, Garner, Staybridge Suites, and Candlewood Suites.
About Vinhomes
Vinhomes is Vietnam’s leading real estate developer, pioneering the development of large-scale, well-planned urban areas with integrated amenities, green living environments, and modern lifestyles. In addition to 36 urban developments currently in operation nationwide, Vinhomes continues to focus on building next-generation mega and super urban developments of regional scale and significance, aspiring to create some of the most livable cities in the world while significantly transforming Vietnam’s urban landscape.
For more information, please visit https://vinhomes.vn/vi
-
Feature/OPED6 years agoDavos was Different this year
-
Travel/Tourism10 years ago
Lagos Seals Western Lodge Hotel In Ikorodu
-
Showbiz3 years agoEstranged Lover Releases Videos of Empress Njamah Bathing
-
Banking8 years agoSort Codes of GTBank Branches in Nigeria
-
Economy3 years agoSubsidy Removal: CNG at N130 Per Litre Cheaper Than Petrol—IPMAN
-
Banking3 years agoSort Codes of UBA Branches in Nigeria
-
Banking3 years agoFirst Bank Announces Planned Downtime
-
Sports3 years agoHighest Paid Nigerian Footballer – How Much Do Nigerian Footballers Earn